HeatBiologicsvaccine

2020年12月16日 — The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product ...

Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19. December 16, 2020 at 4:30 AM PST. Share this article. Copied. Gift this article.

Heat Biologics has licensed patents from the University of Miami that it will use to develop vaccines against the Zika virus.

2021年11月30日 — Heat Biologics, Inc. recently unveiled its new RapidVax cellular vaccine platform at the 2021 World Antiviral Congress.

RapidVax leverages another proprietary vaccine platform developed by Heat called gp96, which primes living cells to activate immune responses against cancer and ...

2021年11月30日 — RapidVax is designed as a rapid programmable vaccine to target a comprehensive range of emerging biological threats. Heat is showcasing a poster ...

... vaccine, today announced a planned reverse stock split of its shares of ... Heat Biologics is a biopharmaceutical company focused on developing first-in ...

由 L Padula 著作 · 2022 — Our allogeneic cellular vaccine, based on a secreted form of the heat-shock protein gp96-Ig, achieves high frequencies of polyclonal CD8 + T cell responses to ...

2020年8月3日 — Heat's vaccine will use a genetically engineered combination of a common protein already found in human cells called gp96, along with viral ...

2020年8月3日 — Waisman Biomanufacturing at the University of Wisconsin–Madison is partnering with Heat Biologics to produce a COVID-19 vaccine for phase 1 and